As of November 6, 2026, Vertex Pharmaceuticals Inc. is a publicly traded company (Nasdaq: VRTX); its largest reported holder is Capital World Investors, with 10.1% on Schedule 13G/A of May 14, 2026, then Capital Research Global Investors (8.3%). The largest insider holding is Reshma Kewalramani, the chief executive and president, with 98,278 shares (0.04% of shares outstanding), per Form 4 of March 3, 2026 (Schedule 13G/A, May 14, 2026).
Is this your company?
About to sign with, pay or invest in Vertex Pharmaceuticals Inc.? See the free Snapshot first.
Free to see. No signup.
Is Vertex Pharmaceuticals Inc. a real, registered company?
- Vertex Pharmaceuticals Inc. files with the SEC under CIK 875320 (its SEC filings).
- Its shares are listed under the ticker VRTX on Nasdaq (SEC company record).
- Incorporated in Massachusetts; business address in Boston, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Vertex Pharmaceuticals Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Daniel Brennan, Director (Form 8-K filed 2026-10-20). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Capital Research Global Investors (filed 2026-05-14).
Who are Vertex Pharmaceuticals Inc.'s owners and officers?
Vertex Pharmaceuticals Inc.: incorporated in Massachusetts; business address in Boston, Massachusetts; industry Pharmaceutical Preparations (Form D, 2026-10-20).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-05-14 | Capital Research Global Investors | 8.3% |
| Schedule 13G/A, 2026-05-14 | Capital World Investors | 10.1% |
| Schedule 13G, 2026-04-30 | Vanguard Capital Management | 7.49% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-12 | Capital Research Global Investors | 6.8% |
Questions about who owns Vertex Pharmaceuticals Inc.
Who owns Vertex Pharmaceuticals Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Vertex Pharmaceuticals Inc.: Capital World Investors (10.1%, Schedule 13G/A, filed 2026-05-14), Capital Research Global Investors (8.3%, Schedule 13G/A, filed 2026-05-14) and Vanguard Capital Management (7.49%, Schedule 13G, filed 2026-04-30).
Who are the largest shareholders of Vertex Pharmaceuticals Inc.?
By the share each holder's latest filing reports, the largest holders of Vertex Pharmaceuticals Inc. on this page are Capital World Investors (10.1%), Capital Research Global Investors (8.3%) and Vanguard Capital Management (7.49%).
When did Capital World Investors buy into Vertex Pharmaceuticals Inc.?
The filings give report dates, not purchase dates. The earliest filing from Capital World Investors on this page is the Schedule 13G/A, filed 2026-05-14, reporting 10.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Vertex Pharmaceuticals Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Vertex Pharmaceuticals Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Vertex Pharmaceuticals Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-10-20 | Daniel Brennan | Director | appointed | |
| Form 8-K, 2026-09-01 | Jonathan Poole | Chief Financial Officer | appointed | 2027-01-01 |
| Form 8-K, 2026-04-29 | Suketu Upadhyay | Director | departed |
Which insiders own Vertex Pharmaceuticals Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 98,278 shares (0.04% of shares outstanding) (Form 4, 2026-03-03).
- , the executive vice president chief patient and ext af officer: 74,031 shares (0.03% of shares outstanding), 66,512 held directly and 7,519 indirectly (Form 4, 2026-07-23).
- , the chief operating officer and executive vice president: 63,508 shares (0.03% of shares outstanding), 63,368 held directly and 140 indirectly (Form 4, 2025-07-02).
- , the executive vice president and chief reg.: 53,572 shares (0.02% of shares outstanding) (Form 4, 2026-07-23).
- , the executive vice president and co: 47,042 shares (0.02% of shares outstanding) (Form 4, 2026-02-26).
Shares outstanding: 253,537,674 as of 2026-10-31, from the company's latest SEC cover page.
How much has Vertex Pharmaceuticals Inc. raised?
No fundraising or offering filing from Vertex Pharmaceuticals Inc. is on file with us.
Keep reading
More on Vertex Pharmaceuticals Inc. and the records around it.
Vertex Pharmaceuticals Inc. elsewhere on the record
- Leadership changes Sep 2026
Companies that share a holder
- Capital Research Global Investors also filed stake reports on 99 other companies: Royal Caribbean Cruises Ltd. (Oct 2026), Patria Investments Ltd. (Sep 2026), Arxis, Inc. (Aug 2026)
- Capital World Investors also filed stake reports on 125 other companies: New Fortress Energy Inc. (Oct 2026), Aura Minerals Inc. (Oct 2026), Skyworks Solutions, Inc. (Oct 2026)
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/vertex-pharmaceuticals